Moody Aldrich Partners LLC reduced its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 9.2% in the fourth quarter, Holdings Channel reports. The firm owned 66,866 shares of the company’s stock after selling 6,767 shares during the period. Moody Aldrich Partners LLC’s holdings in Axsome Therapeutics were worth $5,322,000 at the […]
HC Wainwright reissued their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report released on Tuesday morning, Benzinga reports. They currently have a $190.00 price objective on the stock. Other analysts have also recently issued reports about the company. UBS Group initiated coverage on Axsome Therapeutics in a report on […]
Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) COO Mark L. Jacobson sold 24,662 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $77.24, for a total value of $1,904,892.88. The sale was disclosed in a filing with the Securities & Exchange Commission, […]
Axsome Therapeutics (NASDAQ:AXSM – Free Report) had its target price raised by HC Wainwright from $180.00 to $190.00 in a research report sent to investors on Tuesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Axsome Therapeutics’ Q2 2024 earnings at ($1.08) EPS, Q3 […]
Truist Financial restated their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report issued on Tuesday, Benzinga reports. The brokerage currently has a $150.00 price target on the stock. AXSM has been the topic of a number of other reports. Cantor Fitzgerald reaffirmed an overweight rating and set a $108.00 […]